ClinicalTrials.gov
public full text
Public Domain
A Multicenter Study to Evaluate Safety and Immunogenicity of a Live-attenuated Chikungunya Vaccine in Adolescents
This was a prospective, randomized, double-blinded, multicenter, pivotal study evaluating the full dose of VLA1553 (1 x10E4 TCID50 per dose) in comparison to a placebo control. The dose of VLA1553 or control was administered as single vaccination on Day 1. Overall, approximately 750 male and female participants aged 12 years to \<18 years were enrolled into the study. After completion of the trial, a Post Trial Access program was performed to offer the VLA1553 vaccine to all placebo recipients.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults#829624
- Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy Adults#898874
- Chikungunya Virus Vaccine Trial in Healthy Adults#180224
- Trial for Safety and Immunogenicity of a Chikungunya Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults#640454
- A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.#651121
Record · ID 1371705
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive